Human Growth Hormone hGH Market Report 2023 (Global Edition)

Global Human Growth Hormone hGH Market Report 2023 talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Human Growth Hormone hGH Industry growth. Human Growth Hormone hGH market has been segmented with the help of its Type, Application Route of Administration, and others. Human Growth Hormone hGH market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.

Report scope is customizable as we have a huge database of Human Growth Hormone hGH industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.

Type Segment Analysis of Human Growth Hormone hGH Market

Based on present and future trends, the market size is estimated from 2018 to 2030. Moreover, study also provides quantitative and qualitative analysis of each type to understand the driving factors for the fastest growing type segment for Human Growth Hormone hGH market.

Type of Human Growth Hormone hGH analyzed in this report are as follows:

• Recombinant Human Growth Hormone rhGH
• Human Growth Hormone rhGH

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Human Growth Hormone hGH Industry. Request a Free Sample PDF!

Synthetic human growth hormone was developed in 1985, but FDA approved the usage of drug only for specific disorders. For instance, it is commonly used in children for treating short stature of unknown cause as well as poor growth due to a number of medical causes.Further, awareness regarding turner syndrome is rising and thus hGH use in this syndrome is creating opportunities for the growth of market.

The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Human Growth Hormone hGH market report 2023 Edition by contacting our team.

Human Growth Hormone hGH Route of Administration Segment Analysis

Injecting hGH directly into muscles results in quick absorption of hormone in bloodstream. Because there is more blood in muscle tissue. Moreover, holding capacity of muscle tissue is relatively more than skin tissue. Hence hGH is widely given intramuscular route of administration.

• Intravenous
• Intramuscular
• Subcutaneous
• Oral

Human Growth Hormone hGH Distribution Channel Segment Analysis

By Distribution Channel:

Hospital pharmacy dominate the market in terms of distribution of hGH. This can be attributed owing to large population visit hospitals for the treatment of growth disorders.

• Hospital Pharmacy
• Retail Pharmacy
• Clinics
• Online Pharmacy

Asia Pacific is anticipated to witness highest CAGR in Human Growth Hormone hGH market during the forecast period:

North America is predicted to make up the greatest portion of the market due to excellent reimbursement conditions, an established healthcare infrastructure, considerable government initiatives, and rising healthcare awareness. The presence of major firms in the area also facilitates greater access to innovative medications, which benefits the North American market. Several major companies with U.S. headquarters, including Pfizer, Inc., Eli Lilly and Company, and Genentech, Inc., provide a variety of human GH medicines in the area.However, Asia-Pacific is expected to register the highest CAGR in terms of revenue during the forecast period, owing to the increase in population and rise in awareness amongst the population.

Region-wise, the market is analyzed across: (In case you wish to acquire a specific region or any country data then please contact us)

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!

Key Developments:

• November 2022:

Lumos' oral growth hormone drug falls short of Novo's injectable incumbent at interim analysis
Texas-based Lumos is developing the drug candidate LUM-201, a small molecule that Merck previously studied in patients with growth hormone deficiency, in the belief it promotes secretion of the hormone from the pituitary gland. However, the oral treatment of Lumos Pharma has failed to match up to Novo Nordisk’s injected drug Norditropin at the interim analysis of a phase 2 trial. But with growth in the Norditropin arm exceeding expectations, Lumos has pinned the blame on baseline imbalances.

• September 2019:

Novo Nordisk’s somapacitan shows favourable profile in GHD trial
The company has reported positive data from the Phase II REAL 3 clinical trial of somapacitan in children with growth hormone deficiency (GHD). The drug has demonstrated safety, efficacy and tolerability comparable to that of once-daily Norditropin (somatropin) after one year. An improved efficacy has been reported for the highest somapacitan dose.

• May 2016:

Genentech has received approval for hGH in USA:
Genentech has received approval to market its recombinant human growth hormone product, Nutropin, for the treatment of short stature caused by GH deficiency in the USA. The approval came on the same day that Eli Lilly's period of orphan drug exclusivity for its Humatrope (somatropin) product ran out.
Nutropin was Genentech's second hGH product in the market - its Protropin version, first launched in 1985, is slightly different in structure.

• January 2022:

FDA snubs new growth deficiency med somatrogon, developed by Pfizer and partner OPKO Health:
The FDA has rejected somatrogon, a potential treatment for pediatric growth hormone deficiency. Pfizer lost a first-mover advantage for a long-acting pediatric growth hormone deficiency drug in the U.S. when Ascendis Pharma won an FDA go-ahead in August for Skytrofa, which is also given once every week.
    
 

Top Companies Market Share in Human Growth Hormone hGH Industry: (In no particular order of Rank)

• Eli Lilly and Company
• Ferring Holding SA
• Genentech
• Merck Co.
• Novo Nordisk
• Pfizer
• Sandoz International GmbH
• Ipsen
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables..